PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Herring, W, Gould, IG, Ruiz, L, Dort, T, Zhang, Y, Acosta, C, Hyde, R, Spelman, T, Butzkueven, HVolume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.2022
Date:
October, 2018
File:
PDF, 374 KB
english, 2018